The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse

Journal of Hypertension

Volumn 18, Issue 10, 2000, Pages 1429-1436

  Cristofori, Patrizia ^a   Lanzoni, Anna ^a   Quartaroli, Mauro ^a   Pastorino, Antonio M ^a   Zancanaro, Carlo ^b   Cominacini, Luciano ^b   Gaviraghi, Giovanni ^a   Turton, John ^c  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ApoE deficient mouse; Atherosclerosis; Calcium channel blocker; Lacidipine; Plaque

Indexed keywords

APOLIPOPROTEIN E; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; LACIDIPINE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HYPERTENSION; INFLAMMATION; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033793333     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018100-00010     Document Type: Article

References (43)

1. Menopause and the risk of coronary heart disease in women
2. Update on the pathogenesis of atherosclerosis
3. The pathogenesis of atherosclerosis: A perspective for the 1990s
4. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
5. Evidence that has been or should be considered for guidelines on antihypertensive treatment
6. Calcium, calcium antagonists and experimental atherogenesis
7. Suppression of atherosclerosis in cholesterol-fed rabbits treated with nifedipine
8. Effect of calcium antagonists on lipids and atherosclerosis
9. Atherogenesis, calcium and calcium antagonists
10. The antiatherogenic potential of calcium antagonists: Experimental evidence
11. Molecular interactions between lacidipine and biological membranes
12. Lacidipine: A dihydropyridine calcium antagonist with antioxidant activity
13. The antiatherosclerotic effects of calcium antagonists
14. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolemic rabbits
15. Effect of lacidipine on model of atherosclerosis
16. Effect of lacidipine on cholesterol esterification: In vivo and in vitro studies
17. Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits
18. Anti-atherosclerotic activity of the calcium antagonist lacidipine in cholesterol-fed hamsters
19. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells
20. Spontaneous hypercholes-terolemia and arterial lesions in mice lacking apolipoprotein E
21. Quantitation of atherosclerosis in murine models: Correlation between lesions in the aortic origin and the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice
22. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
23. The mouse as a model for human cardiovascular disease and hyperlipidemia
24. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification
25. The role of endothelin in coronary atherosclerosis
26. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats
27. Animal models of atheresclerosis and interpretation of drug intervention studies
28. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
29. Endothelin ET(A)receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
30. Serum platelet-derived growth factor and endothelin concentrations in human hypercholesterolemia
31. Elevated endothelin levels in patients with hyperlipoproteinemia
32. Circulating immunoreactive endothelin in ischemic heart disease
33. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
34. Increased endothelin plasma concentration in patients with coronary artery disease or hyperlipoproteinemia without coronary events
35. Mode of action of probucol in reducing serum cholesterol in mice
36. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice
37. Calcium antagonists as anti-atherosclerotic agents
38. Lacidipine, a 1, 4-dihydropyridine calcium entry blocker interferes with endothelin at different levels
39. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
40. Regulation of endothelin-1 gene expression by Fos and Jun
41. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor
42. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: Inhibitory effect of lacidipine
43. The role of endothelin in atherosclerosis